Zobrazeno 1 - 10
of 26
pro vyhledávání: '"E.-M. Fuchs"'
Publikováno v:
The International Archives of the Photogrammetry, Remote Sensing and Spatial Information Sciences, Vol XL-7/W3, Pp 797-804 (2015)
This paper introduces fire monitoring works of two different projects, namely TIMELINE (TIMe Series Processing of Medium Resolution Earth Observation Data assessing Long –Term Dynamics In our Natural Environment) and PHAROS (Project on a Multi-Haza
Externí odkaz:
https://doaj.org/article/ead8b2a9328e447c98126dbe684a2f90
Autor:
Piotr J. Wysocki, Christian F. Singer, S Debska, Reinhard Horvat, B. Arlukowicz-Czartoryska, Christos J. Petropoulos, Wolfgang J. Köstler, Barbara Szostakiewicz, Maria Litwiniuk, Jeff Sperinde, Suhail M. Ali, T Jankowski, Kim Leitzel, E-M Fuchs, Wei Huang, Wojciech Biernat, Mojgan Haddad, Barbara Radecka, John Winslow, A. Lipton, Małgorzata Foszczyńska-Kłoda, A. Paquet, Jodi Weidler, Yolanda Lie, Jacek Jassem, Renata Duchnowska
Publikováno v:
Cancer Research. 72:P2-10
Background: Expression of p95HER2 (p95), a truncated form of HER2 also known as p110 or M611-CTF, is a possible trastuzumab resistance mechanism and has been associated with poor prognosis in trastuzumab-treated HER2-positive metastatic breast cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c6a148e9bc7bdc82eecbe9c22fd835ee
https://doi.org/10.1158/0008-5472.sabcs12-p2-10-31
https://doi.org/10.1158/0008-5472.sabcs12-p2-10-31
Autor:
A. Lipton, Suhail M. Ali, A Laadem, Matthew L. Sherman, W. Koestler, Lindsey Zubritsky, Kim Leitzel, Rob Knight, E-M Fuchs, Luciano J. Costa
Publikováno v:
Cancer Research. 72:P3-06
Background: Only half of HER2-positive metastatic breast cancer patients will respond to first-line trastuzumab-containing therapy, but of these, most will progress within a year. Trastuzumab resistance remains a continuing clinical problem, and bett
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b7e5db48cef4fac742a5db793c8e0c9c
https://doi.org/10.1158/0008-5472.sabcs12-p3-06-33
https://doi.org/10.1158/0008-5472.sabcs12-p3-06-33
Autor:
Suhail M. Ali, Allan Lipton, James D. Connor, Cynthia Campbell-Baird, Kim Leitzel, W. Koestler, Ahmed Alkhateeb, E-M Fuchs, Matt Evans
Publikováno v:
Cancer Research. 71:P5-14
Background: Approximately one-half of HER2−positive breast cancer patients will not respond to first-line trastuzumab-containing therapy. Since trastuzumab is now used in the HER2−positive adjuvant breast cancer setting, trastuzumab resistance wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::157a0ab783c94f4f418ec844edbb78e2
https://doi.org/10.1158/0008-5472.sabcs11-p5-14-11
https://doi.org/10.1158/0008-5472.sabcs11-p5-14-11
Autor:
Suhail M. Ali, Syed Rizvi, R Kalu, V Shrinvastava, A. Lipton, K Repich, Matt Evans, Sheryl Brown-Shimer, Peter J. Hamer, E-M Fuchs, U. Anyanwu, Kim Leitzel, Jessica Ramirez, W. Koestler, H. Y. Hou, Walter P. Carney
Publikováno v:
Cancer Research. 70:P2-09
Background: Approximately one-half of HER2-positive breast cancer patients will respond to first-line trastuzumab-containing therapy. However, in those patients with an initial trastuzumab response, most will progress within a year with acquired resi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::060e5a5e28171de19fe107f9eed4fc0e
https://doi.org/10.1158/0008-5472.sabcs10-p2-09-07
https://doi.org/10.1158/0008-5472.sabcs10-p2-09-07
Autor:
Ernst Kubista, E-M Fuchs, Reinhard Horvat, Wolfgang J. Köstler, Gernot Hudelist, Cf. Singer, Christoph C. Zielinski
Publikováno v:
Cancer Research. 70:PD10-04
Background: Despite patient selection based on ERBB2 overexpression, response to trastuzumab-based therapy is not always achieved. The reasons for response failure to ERBB2-targeted therapy are still largely unknown. We have investigated whether a ge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa8ad39c63e58120cc0c5aa1df32f59d
https://doi.org/10.1158/0008-5472.sabcs10-pd10-04
https://doi.org/10.1158/0008-5472.sabcs10-pd10-04
Publikováno v:
Journal of neonatal-perinatal medicine. 7(2)
Umbilical vessel catheterization is common practice for infants in the neonatal intensive care unit (NICU). Umbilical venous catheters (UVC) although very useful as a means of obtaining vascular access, do not come without risks. Here we will describ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82a2200e4ad71a127beb449839c3d550
https://pubmed.ncbi.nlm.nih.gov/25104128
https://pubmed.ncbi.nlm.nih.gov/25104128
Autor:
Christopher T. Elliott, Dirk Courtheyn, Mirjam Nielen, H. Hooijerink, S. A. Boyd, M. L. Essers, E.O. van Bennekom, R. E. M. Fuchs
Publikováno v:
Rapid Communications in Mass Spectrometry 17 (2003) 14
Rapid Communications in Mass Spectrometry, 17(14), 1633-1641
Rapid Communications in Mass Spectrometry, 17(14), 1633-1641
A new approach to the search for residues of unknown growth promoting agents such as anabolic steroids and beta-agonists in feed is presented. Following primary extraction and clean-up, samples are separated using gradient liquid chromatography (LC).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7574fa7d8adeadaff1b0701426b4ab09
https://pubmed.ncbi.nlm.nih.gov/12845590
https://pubmed.ncbi.nlm.nih.gov/12845590
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.